RANK signalling in bone lesions with osteoclast-like giant cells

Pathology

Volumn 43, Issue 4, 2011, Pages 318-321

  Won, Kyu Yeoun ^a,b   Kalil, Ricardo Karam ^d,e   Kim, Youn Wha ^a   Park, Yong Koo ^a,b,c  

^a Kyung Hee University College of Medicine   (South Korea)

^b Department of Biochemistry and Molecular Biology   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Medical Science and Engineering Research Center for Bioreaction to Reactive Oxygen Species   (South Korea)

^e SARAH NETWORK OF REHABILITATION HOSPITALS   (Brazil)

Author keywords

Giant cells; OPG; RANK; RANKL

Indexed keywords

EID: 80052252590     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283463536     Document Type: Article

References (13)

1. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9. (Pubitemid 27507987)
2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identicalto TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
3. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19. (Pubitemid 27199902)
4. Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25. (Pubitemid 43089652)
5. Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167: 117-28. (Pubitemid 40884775)
6. Fanning CV, Sneige NS, Carrasco CH, et al. Fine needle aspiration cytology of chondroblastoma of bone. Cancer 1990; 65: 1847-63. (Pubitemid 20116662)
7. Huang L, Cheng YY, Chow LT, et al. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 2003; 56: 116-20. (Pubitemid 36461472)
8. Oliveira AM, Perez-Atayde AR, Dal Cin P, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005; 24: 3419-26. (Pubitemid 40756243)
9. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704: 49-57. (Pubitemid 39195349)
10. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-37. (Pubitemid 28510154)
11. Atkins GJ, Bouralexis S, Haynes DR, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001; 28: 370-7. (Pubitemid 32385408)
12. Huang L, Xu J,Wood DJ, et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000; 156: 761-7. (Pubitemid 30626932)
13. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.